{"retracted":false,"update":{"timestamp":1407369600000,"doi":"10.1007/s40620-014-0128-2","type":"correction"},"doi":"10.1007/s40620-014-0122-8","journal":"Journal of Nephrology","publisher":"Springer Nature","title":"Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study"}
